Table 6 Deterministic sensitivity analysis results according to PFS. Amounts are presented in MXN pesos
TKI | Mean total cost | Incremental Cost | Effectiveness | Incremental Effectiveness | ICER |
|---|---|---|---|---|---|
5% discount (case-base) | |||||
Gefitinib | $161,800.00 | – | 8.18 | – | – |
Erlotinib | $215,700.00 | $53,900.00 | 6.70 | −1.48 | Dominated |
Afatinib | $348,200.00 | $186,400.00 | 9.46 | 1.28 | $145,625.00 |
No discount (0%) | |||||
Gefitinib | $206,502.36 | – | 10.44 | – | – |
Erlotinib | $275,293.93 | $68,791.58 | 8.55 | −1.89 | Dominated |
Afatinib | $444,401.24 | $237,898.88 | 12.07 | 1.63 | $145,625.00 |
3% discount | |||||
Gefitinib | $139,570.10 | – | 7.06 | – | – |
Erlotinib | $186,064.71 | $46,494.61 | 5.78 | −1.28 | Dominated |
Afatinib | $300,360.38 | $160,790.28 | 8.16 | 1.10 | $145,625.00 |
7% discount | |||||
Gefitinib | $115,361.16 | – | 5.83 | – | – |
Erlotinib | $153,791.12 | $38,429.96 | 4.78 | −1.06 | Dominated |
Afatinib | $248,261.79 | $132,900.62 | 6.74 | 0.91 | $145,625.00 |